Streetbeat News

Stock Prices

SNPX

Synaptogenix announced a 1-for-25 reverse stock split, leading to its shares trading lower.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:07 pm

JZXN

Trading of Jiuzi Holdings shares, symbol JZXN, has resumed.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:03 pm

IMXUSD

Immutable's cryptocurrency (CRYPTO: IMX) has seen a price increase of 3.36% in the last 24 hours, reaching $2.77, despite a 7.0% decrease over the past week from $2.93. The coin's all-time high is $9.52. Trading volume has decreased by 42.0% over the past week, and the circulating supply has slightly decreased by 0.16% to over 1.42 billion, which is 71.15% of its max supply of 2.00 billion. Currently, IMX's market cap ranks it at #34 with a value of $3.93 billion.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:02 pm

CROUSD

Cronos (CRO) experienced a significant price increase of 8.81% over the past 24 hours, reaching $0.15. Over the last week, its price has also risen by over 2.0%. The coin's all-time high is $0.97. Trading volume has increased by 2.0% in the past week, while the circulating supply decreased by 1.74%, now standing at 26.63 billion. Cronos's market cap is currently ranked #31 at $4.11 billion.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:02 pm

PSX

Phillips 66 (NYSE:PSX) has increased its quarterly dividend from $1.05 to $1.15 per share, a 10% rise, payable on June 3, 2024, to shareholders of record as of May 20, 2024. This decision reflects the company's confidence in its financial growth and commitment to shareholder value, with plans to return $13 billion to $15 billion to shareholders through dividends and share repurchases by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:02 pm

AZN

AstraZeneca (NASDAQ:AZN) has seen a bullish trend in its options market, with 62% of traders showing bullish sentiment. The analysis revealed 8 unusual trades, with a notable preference for puts over calls in terms of value. The expected price range for AZN over the next three months is between $62.5 and $67.5. The largest trades observed include both bullish and bearish sentiments, with significant activity around the $62.5 to $67.5 strike prices. AstraZeneca's current stock price is $67.19, with an upcoming earnings announcement in 22 days.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:01 pm

BG

Analyst ratings for Bunge Global (NYSE:BG) show diverse outlooks, with recent evaluations indicating a shift towards a more cautious stance. The average 12-month price target has been adjusted to $119.78, marking a 10.61% decrease from the previous target of $134.00. Despite this, the majority of analysts remain bullish. Bunge Global's financial overview reveals a strong market presence but a negative revenue trend, with a -15.11% growth over 3 months. However, its net margin, ROE, and ROA outperform industry averages, indicating efficient cost management and financial health.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:01 pm

STXUSD

Stacks (CRYPTO: STX) has seen a 6.74% decrease in price over the last 24 hours, continuing a negative trend with a 3.0% loss over the past week. Despite this, trading volume has increased by 13.0%, and the circulating supply has slightly risen. Stacks's market cap ranks it at #27 with a value of $4.73 billion.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:01 pm

LLY

Financial analysis reveals a bearish trend in options trading for Eli Lilly and Co (NYSE:LLY), with 73% of trades showing bearish tendencies. The price target for LLY is set between $430.0 and $900.0. The largest options trades indicate a focus on strike prices ranging from $700 to $785. Eli Lilly, a drug firm, has seen its stock price slightly increase by 0.2% to $765.5. Analyst ratings in the last month have an average target price of $852.5, with ratings from JP Morgan, Citigroup, Truist Securities, and Cantor Fitzgerald.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:01 pm

ADM

In the past three months, 13 analysts have updated their ratings on Archer-Daniels Midland (NYSE:ADM), with the majority maintaining a neutral stance. The 12-month price targets show a significant decrease, with the current average at $62.62, down from $87.09. Analysts have adjusted their ratings and price targets in response to market dynamics and ADM's performance, including a notable -11.42% decline in revenue growth and strong financial indicators such as net margin and ROE. ADM is a major agricultural commodity processor and grain merchandiser, facing challenges but also demonstrating financial health through efficient cost management and asset utilization.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:01 pm